BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Immunology

Akeso Begins Phase III Trial of Ivonescimab for Hard-to-Treat Advanced Colorectal Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully enrolled in the registration Phas...

July 16, 2025 | News

Concord Healthcare Delivers China’s First Proton Therapy for Choroidal Malignant Melanoma

Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), whic...

July 15, 2025 | News

Elegen and Nutcracker Therapeutics Launch Cell-Free Platform Pilot to Transform RNA-Based Personalised Cancer Therapeutics

Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufactu...

July 14, 2025 | News

BioMed X and Servier Launch Europe’s First XSeed Labs at Paris-Saclay to Accelerate AI-Driven Bispecific Antibody Design

BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced the launch of a new initiative with Se...

July 10, 2025 | News

Inocras Partners with Chi Mei Medical Center and Trivator to Advance Precision Oncology in Taiwan

Inocras Inc., a global leader in whole-genome sequencing (WGS) and bioinformatics, today announced the signing of a Memorandum of Understanding (MOU) with ...

July 09, 2025 | News

Quanterix Completes Acquisition of Akoya Biosciences, Expanding Leadership in Multi-Tissue Biomarker Detection

Quanterix Corporation, a company fueling scientific discovery through ultra-sensitive biomarker detection, announced that it has completed its previously a...

July 09, 2025 | News

Sirtex Secures FDA Approval for SIR-Spheres® Y-90 in Treating Unresectable Hepatocellular Carcinoma

Sirtex Medical ("Sirtex"), a leading manufacturer of interventional oncology solutions, today announced that the U.S. Food and Drug Administration (F...

July 08, 2025 | News

ImmunityBio Secures First International Approval for ANKTIVA® in the UK for Bladder Cancer Treatment

ANKTIVA, a first-in-class, lymphocyte-stimulating agent, works synergistically with BCG to activate and proliferate natural killer (NK) and T cells, he...

July 08, 2025 | News

InnoCare Pharma Receives IND Approval in China for Novel B7-H3 Targeted ADC ICP-B794

InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced the approval of the Inves...

July 07, 2025 | News

Thermo Fisher Secures FDA Approval for Oncomine Dx Express Test as Companion Diagnostic for Dizal’s ZEGFROVY

Thermo Fisher Scientific, the world leader in serving science, announced the U.S. Food and Drug Administration (FDA) has approved the Oncomine&t...

July 04, 2025 | News

Lunit Partners with Microsoft to Scale AI-Powered Cancer Diagnostics Globally

Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, announced a collaboration with Microsoft to accelerate the deliver...

July 03, 2025 | News

Dizal Secures FDA Approval for ZEGFROVY, the First Targeted Oral Therapy for EGFR Exon20ins NSCLC

ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20ins Approval follows the U....

July 03, 2025 | News

Taiwan Steps Into the Global Spotlight With a New Cancer Therapy

Traditional therapies often fall short in targeting these aggressive cancers with precision or safety. Can SOB100 improve drug delivery without the usual s...

July 02, 2025 | Report

AvenCell Secures Up to $40 Million AMED Grant to Advance Dual-Antigen Allogeneic CAR-T Therapy

AvenCell Japan, a wholly owned subsidiary of AvenCell Therapeutics, a private, clinical-stage biotechnology company developing best-in-class CAR-T therapie...

July 02, 2025 | News

Stay Connected